Physician profile
Ryan K Schmocker
NPI 1457639478
$2,024.72
in general payments reported to CMS, 2019-2025
31 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.27 · 2022: $250 · 2023: $390 · 2024: $816 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.81 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $307.29 | 2022-2025 | Ligasure, Emprint |
| Merck Sharp & Dohme LLC | $255.29 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Fujifilm Healthcare Americas Corporation | $222.67 | 2024 | Synapse 3d |
| Astrazeneca Pharmaceuticals LP | $133.73 | 2024-2025 | Imfinzi |
| Genentech USA, INC. | $131.83 | 2023-2025 | Perjeta, Phesgo, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $111.06 | 2022-2025 | Libtayo |
| Intuitive Surgical, INC. | $90.71 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $72.16 | 2022-2024 | Creon |
| Eisai INC. | $71.66 | 2023-2024 | |
| Glaxosmithkline, LLC. | $58.60 | 2023-2024 | Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $56.79 | 2024-2025 | Ninlaro, Fruzaqla |
| Teleflex LLC | $56.51 | 2024-2025 | Quikclot, Quikclot |
| Novartis Pharmaceuticals Corporation | $49.85 | 2024 | |
| Galvanize Therapeutics, INC | $48.54 | 2023 | Aliya System |
| Aveo Pharmaceuticals, INC. | $35.06 | 2023-2025 | Fotivda |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $30.35 | 2024 | |
| Deciphera Pharmaceuticals INC. | $28.43 | 2025 | Qinlock |
| Tela Bio, INC. | $26.72 | 2021 | |
| Olympus America INC. | $26.55 | 2021 | |
| Ethicon US, LLC | $22.48 | 2025 | Vistaseal, Ethicon, Surgiflo Hemostatic Matrix |
| Lilly USA, LLC | $19.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.06 | 2025 | |
| Beone Medicines USA, INC. | $18.68 | 2025 | Tevimbra |
| Exelixis INC. | $18.05 | 2025 | Cabometyx |
| Incyte Corporation | $17.68 | 2024 | Jakafi |
| Kerecis Limited | $17.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Alexion Pharmaceuticals, INC. | $16.58 | 2023 | Ultomiris |
| Stryker Corporation | $16.11 | 2025 | Eikon Lt Adapt Smoke Evacuation, Molli |
| Celgene Corporation | $15.68 | 2022 | |
| Pfizer INC. | $15.67 | 2024 | |
| Janssen Biotech, INC. | $14.29 | 2025 | Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schmocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.